VNRX trade ideas
VNRX Short?Hey everyone,
the price is falling into the triangle, which usually means it leaves in the same direction. The overall trend is downwards. The MA also tells to sell. What you fundamentally sea is your thing, for me it's a sell!
Volition RX - Positive News required to escape the bearcountryTo shorten things and to keep it simple: According to fibunacci should the stock stabilise at around 3.7$ and higher to keep above the 61.8 retracement.
If the company will publish some good news soon, it could be the signal for an entry.
Entryprice above 3.69$
PENNY STOCKS: VolitionRX Ltd - RUN ON ITthis one is ready for playing around
MACD near to 0.4
RSI near to 70
BULLISH
Q3 can be a good timing
$VNRX on watchlist for breakout VolitionRX Ltd. is a multi-national life sciences company. It engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on August 5, 2010 and is headquartered in Singapore.
$VNRX Prepping For A Breakout$VNRX has popped on our radar. $VNRX is trading above its 20, 50, and 200 day moving averages. A breakout to new highs above $3.63 sets $VNRX up for a nice move.
Yesterday, the company put out some news.
AUSTIN, Texas, July 18, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a contract under the previously announced Memorandum of Understanding, with Shanghai Fosun Long March Medical Science Co., Ltd. ("Fosun Long March") to help introduce the Nu.Q(TM) platform to China. Based on recent promising proof-of-concept data using Volition's product-grade Nu.Q assays, the parties have commenced a clinical study in China in lung cancer.
Dr. Jasmine Kway, Chief Executive Officer of Singapore Volition, commented: "We are happy to have executed this agreement with Fosun Long March and are delighted that the clinical study is already underway and expected to be completed by the end of this year."
Dr. Yuejian Zhang, Chairman of Fosun Long March, remarked: "We were impressed with Volition's preliminary data, particularly in lung cancer, and are happy to have started work on these initial clinical studies. Whilst China represents a little under 20% of the world's population, it accounted for almost 24% of cancer diagnoses and 30% of cancer-related deaths worldwide in 2018, almost a third of which were due to lung cancer and colorectal cancer. We look forward to completing this important study and working together with Volition to launch Nu.Q in China."
"The need for a simple, easy to use, cost effective test for cancer is truly universal and we hope very much that our Nu.Q tests can help revolutionize the way cancer is diagnosed worldwide," commented Cameron Reynolds, Chief Executive Officer of Volition. "We see Asia, and particularly lung cancer in China, as a key market for Volition. We are excited about the commencement of our work in China and look forward to a successful collaboration with Fosun Long March."
About Fosun Long March
Established in 1989, Fosun Long March is the investment platform of in-vitro diagnostics division of Fosun Pharma Group and has since accelerated merger and acquisition of new products introduction into China. With its wide range of in-vitro diagnostics products, strength in manufacturing and strong nation-wide sales network, Fosun Long March is one of the most influential brands in in-vitro diagnostics in China.
Fosun Long March's network and expertise will assist Volition with the facilitation and coordination of the collection, provision and testing of blood samples using Volition's proprietary Nu.Q(TM) assays for the clinical studies, with Fosun's hospitals, research institutions and clinics, as well as other third-party hospitals, universities, research institutions and clinics in China.
About Volition
Volition is a multi-national life sciences company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics(TM), which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.
Volition's research and development activities are currently centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.
Bad fundamentals good technicals for VNRXDespite reported second quarter loss of $2.9 million that did not meet Wall street expectations, VNRX (VolitionRX) might look quite bullish in a distant future. Three weeks ago there was a bullish engulfing at the bottom of a enormous rectangle which should imply some bullish momentum. This is why we go long with this stock with TP near the upper boundary of this rectangle.
For more ideas go to mercuriusam.wordpress.com.
DTI8 Patrones: Cuña abajoSe puede apreciar el patron y segun las bandas de bollinger y el RSI todavia no se deberia romper el patron ya que no presenta grandes variaciones en su volatilidad y no se encuentra ni sobrecomprado ni sobrevendido
